Hong Kong Stock Movement | SIHUAN PHARM (00460) Surges Over 4% Again as XUANZHUBIO Launches IPO Today, Company's "Dongyan" Product Receives Market Approval
Stock News
Oct 06
SIHUAN PHARM (00460) surged over 4% again, rising 4.47% to HK$1.87 as of press time, with trading volume reaching HK$66.52 million. On the news front, XUANZHUBIO is conducting its IPO from October 6 to October 10, planning to offer 67.33 million shares globally, with shares expected to commence trading on the Hong Kong Stock Exchange on October 15. XUANZHUBIO was spun off from SIHUAN PHARM. Additionally, SIHUAN PHARM's subsidiary Meiyan Space has recently obtained the National Medical Products Administration's Class III medical device registration certificate for its self-developed "Sodium Hyaluronate Composite Solution for Injection - Dongyan," marking the official entry of China's first L-carnosine composite solution water-light injection into the capital market spotlight.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.